Phenobarbital Sodium

57-30-7 Categories: , ,
  • # LGM Pharma is a Phenobarbital Sodium CAS# 57-30-7 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, samples, sourcing, purity and more.
  • # Questions? Call our customer API support number 1-(800)-881-8210.
  • # LGM Pharma offers this active ingredient but not the finished dosage forms.
  • Inquire about this product >>

Product Details:

  • Product Name: Phenobarbital Sodium
  • CAS #: 57-30-7
  • Mode of Action:

    Phenobarbital acts on GABAA receptors, increasing synaptic inhibition. This has the effect of elevating seizure threshold and reducing the spread of seizure activity from a seizure focus. Phenobarbital may also inhibit calcium channels, resulting in a decrease in excitatory transmitter release. The sedative-hypnotic effects of phenobarbital are likely the result of its effect on the polysynaptic midbrain reticular formation, which controls CNS arousal.

  • Pharmacodynamics:

    Phenobarbital, the longest-acting barbiturate, is used for its anticonvulsant and sedative-hypnotic properties in the management of all seizure disorders except absence (petit mal).

  • Metabolism:

    Hepatic (mostly via CYP2C19).

  • Toxicity:

    CNS and respiratory depression which may progress to Cheyne-Stokes respiration, areflexia, constriction of the pupils to a slight degree (though in severe poisoning they may wshow paralytic dilation), oliguria, tachycardia, hypotension, lowered body temperature, and coma. Typical shock syndrome (apnea, circulatory collapse, respiratory arrest, and death) may occur.

  • IUPAC: 2, 4, 6(1H, 3H, 5H)-Pyrimidinetrione, 5-ethyl-5-phenyl-, monosodium salt Barbituric acid, 5-ethyl-5-phenyl-, sodium salt Phenobarbital sodium
  • ATC: N03AA02
  • PubChem: 4763
  • DrugBank: DB01174
  • Formula: C12-H11-N2-Na-O3, C12-H12-N2-O3.Na
  • Molecular Mass: 254.22
  • Synonyms: 5-Ethyl-5-phenyl-2,4,6-(1H,3H,5H)pyrimidinetrione monosodium salt, 5-Ethyl-5-phenylbarbituric acid sodium salt, CCRIS 503, EINECS 200-322-3, Fenobarbital natrium, Fenobarbital natrium [Polish], Fenobarbital sodico, Fenobarbital sodico [INN-Spanish], Gardenal sodium, Linasen, Luminal sodium, Phenemalnatrium, Phenemalum, Phenobal sodium, Phenobarbital elixir, Phenobarbital Na, Phenobarbital sodique, Phenobarbital sodique [INN-French], Phenobarbital sodium, Phenobarbital sodium salt, Phenobarbitalnatrium, Phenobarbitalum natricum, Phenobarbitalum natricum [INN-Latin], Phenobarbiton-natrium, Phenobarbitone sodium, Phenobarbitone sodium salt, Phenyl-aethyl-barbitursaeure natrium, Phenyl-aethyl-barbitursaeure natrium [German], Phenylethylbarbituric acid, sodium salt, Sodium 5-ethyl-5-phenylbarbiturate, Sodium luminal, Sodium phenobarbital, Sodium phenobarbitone, Sodium phenobarbiturate, Sodium phenylethylbarbiturate, Sodium phenylethylmalonylurea, Sol phenobarbital, Sol phenobarbitone, Soluble phenobarbital, Soluble phenobarbitone, UNII-SW9M9BB5K3
  • SMILES: c1([C@@]2(C(NC([O-])=NC2=O)=O)CC)ccccc1.[Na+]
  • AHFS Code: 28:24.0
  • InChl: 1S/C12H12N2O3.Na/c1-2-12(8-6-4-3-5-7-8)9(15)13-11(17)14-10(12)16;/h3-7H,2H2,1H3,(H2,13,14,15,16,17);/q;+1/p-1
  • General Reference:

    1. Kwan P, Brodie MJ: Phenobarbital for the treatment of epilepsy in the 21st century: a critical review. Epilepsia. 2004 Sep;45(9):1141-9. Pubmed
    2. Taylor S, Tudur Smith C, Williamson PR, Marson AG: Phenobarbitone versus phenytoin monotherapy for partial onset seizures and generalized onset tonic-clonic seizures. Cochrane Database Syst Rev. 2001;(4):CD002217. Pubmed
    3. Tudur Smith C, Marson AG, Williamson PR: Carbamazepine versus phenobarbitone monotherapy for epilepsy. Cochrane Database Syst Rev. 2003;(1):CD001904. Pubmed
    4. Kalviainen R, Eriksson K, Parviainen I: Refractory generalised convulsive status epilepticus : a guide to treatment. CNS Drugs. 2005;19(9):759-68. Pubmed
    5. Booth D, Evans DJ: Anticonvulsants for neonates with seizures. Cochrane Database Syst Rev. 2004 Oct 18;(4):CD004218. Pubmed

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Streamlined API supply towards initial research stages as well as larger quantities of cGMP material for clinical trials and product commercialization
  • Premium quality GMP certified and fully accredited API manufacturing plants


  • Technical packages as well as access to filed DMF,
    ASMF or CEP (subject to availability)
  • Regulatory and technical assistance towards any
    submission type based on specific customer requirements

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service